|
Jun 14
|
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
|
|
Jun 13
|
Vaxart Announces $40 Million Underwritten Offering of Common Stock
|
|
Jun 13
|
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
|
|
May 14
|
Q1 2024 Vaxart Inc Earnings Call
|
|
May 14
|
Vaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ...
|
|
May 13
|
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
May 7
|
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
|
|
Apr 30
|
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
|
|
Apr 9
|
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
|
|
Mar 27
|
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
|
|
Mar 20
|
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 17
|
Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)
|
|
Mar 15
|
Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
Q4 2023 Vaxart Inc Earnings Call
|
|
Mar 14
|
Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results
|
|
Mar 14
|
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
|
|
Mar 7
|
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
|
|
Mar 6
|
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
|
|
Feb 26
|
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
|
|
Feb 5
|
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
|